Table 4. Comparing change in FVC (% predicted) from baseline to week 12 at Site 001 GALS-001 patients between placebo and GM604 treated groups.

¹P-values were calculated by two-sample t Test. ²The P-value was obtained from a Wilcoxon Rank Sum Test.

Time Point	Site 001 Placebo	Site 001 GM604
Baseline
N	2	4
Mean	73.5	89.5
Week 12 N
N	2	4
Mean	45.5	84.8
Change from Baseline N
N	2	4
Mean	-28	-4.7
1P-values Two- sample t Test		0.0268
2P-values Wilcoxon Rank Sum Test		0.1052